Human parvovirus B19 has a strong tissue tropism for erythroid progenitor cells and is a causative agent for anemia. However, it remains unclear whether patients with hematological disorders are at a higher risk of B19 infection. In the present study, we evaluated the prevalence of B19 infection in 278 patients with hematological disorders by indirect antibody capture enzyme-linked immunosorbent assay. Virus inoculation into cell culture (of TF-6, WRL-68, and HL-60) was carried out using serum from patients with positive IgM anti-B19 and was then examined by nested polymerase chain reaction, dot-blot analysis, and sequence analysis. Our data demonstrated that the total seropositive rates of either IgG or IgM were 71.9%. The seropositive rates increase significantly with age (P < 0.001). After adjustment for age, the seropositive rate was significantly higher in our patients than in the general population with standardized rate ratio of 1.56 (95% CI = 1.43-1.68). No significant difference was found among different disease subgroups (P = 0.311). Nine patients (3.2%) had active B19 infection with positive IgM antibody, with four diagnosed as having idiopathic thrombocytopenic purpura (ITP). Viremia of B19 virus could be detected in eight of nine patients, including three patients in serum only, three patients in bone marrow only, and two patients in both serum and bone marrow. We conclude that patients with hematological disease have higher seropositive rates for B19 than occur in normal controls and that study of occult parvovirus B19 infection is recommended in patients with hematological disease.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/jmv.10517 | DOI Listing |
Int Immunopharmacol
January 2025
Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan; Department of Clinical Laboratory, Chung Shan Medical University Hospital, Taichung 402, Taiwan; Immunology Research Center, Chung Shan Medical University, Taichung 402, Taiwan. Electronic address:
Parvovirus B19 (B19V) is a human pathogen from the Parvoviridae family that primarily targets and replicates in erythroid progenitor cells (EPCs). While its symptoms are typically self-limiting in healthy individuals, B19V can cause or exacerbate autoimmune diseases in vulnerable patients. This review integrates the involvement of B19V in the development and worsening of several autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), hematological disorders (thalassemia, anemia, and thrombocytopenia), vasculitis, antiphospholipid syndrome (APS), dermatological disease (systemic sclerosis, psoriasis), autoimmune thyroid disease, myocarditis, and myasthenia gravis, and autoinflammatory disease of adult-onset Still's disease (AOSD).
View Article and Find Full Text PDFVaccine
December 2024
Mucosal Immunoogy Laboratory, Biomedicine Research Unit, Faculty of Higher Studies Iztacala, National Autonomous University of Mexico. Avenida de los Barrios 1, Los Reyes Iztacala, Tlalnepantla, Estado de México 54090, Mexico. Electronic address:
The development of a protective HIV vaccine remains a challenge given the high antigenic diversity and mutational rate of the virus, which leads to viral escape and establishment of reservoirs in the host. Modern antigen design can guide immune responses towards conserved sites, consensus sequences or normally subdominant epitopes, thus enabling the development of broadly neutralizing antibodies and polyfunctional lymphocyte responses. Conventional epitope vaccines can often be impaired by low immunogenicity, a limitation that may be overcome by using a carrier system.
View Article and Find Full Text PDFItal J Pediatr
December 2024
Department of Pediatrics, Santa Maria delle Croci Hospital, AUSL della Romagna, Viale Vincenzo Randi, 5, Ravenna, Ravenna, 48121, RA, Italy.
Parvovirus B19 (B19V) is a significant pathogen responsible for a wide range of clinical manifestations, particularly in children and pregnant women. While B19V is most commonly recognized as the cause of Fifth disease, a mild erythematous illness in children, its clinical impact extends far beyond this condition. B19V can lead to severe complications, including transient aplastic crisis in individuals with chronic hemolytic anemias, arthralgia, and more severe joint diseases.
View Article and Find Full Text PDFCEN Case Rep
December 2024
Department of Nephrology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami, Sagamihara, Kanagawa, 252-0375, Japan.
Several cases of glomerulonephritis occurring after infection with human parvovirus B19 (PVB19) have been reported. However, the pathogenesis and clinicopathological features of PVB19-related glomerulonephritis remain elusive. We describe the case of a 34 year-old woman who showed nephrotic syndrome and microscopic hematuria 10 days after PVB19 infection.
View Article and Find Full Text PDFPediatr Infect Dis J
December 2024
Department of Pediatric Infectious Diseases, Katip Çelebi University, İzmir, Turkey.
Human parvovirus B19 typically causes erythema infectiosum, but unusual exanthems and hemorrhagic manifestations, such as purpuric-petechial rashes, have also been reported. PVB19-associated purpuric-petechial eruption (PAPPE) should be recognized as a distinct clinical feature of primary parvovirus B19 infection and considered in the differential diagnosis of patients with febrile purpura. This report aims to highlight several scenarios of B19V-associated petechial and purpuric rashes, which may present to pediatric departments during outbreaks.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!